A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Arcus Biosciences, Inc.
AstraZeneca
City of Hope Medical Center
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
M.D. Anderson Cancer Center
ImmunityBio, Inc.
Northwestern University
AstraZeneca
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)